Of mice and men (and women) and the acylation-stimulating protein pathway

Current Opinion in Lipidology

Volumn 11, Issue 3, 2000, Pages 291-296

  Sniderman, Allan D ^a   Maslowska, Magdalena ^a   Cianflone, Katherine ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLATION STIMULATING PROTEIN; FATTY ACID; INSULIN; LIPOPROTEIN LIPASE; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACYLATION; ADIPOCYTE; ENERGY; ENZYME REGULATION; FEMALE; HUMAN; HYDROLYSIS; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOCYTES; ANIMALS; APOLIPOPROTEINS B; BLOOD PROTEINS; COMPLEMENT C3A; FATTY ACIDS; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MICE; MICE, KNOCKOUT; TRIGLYCERIDES;

EID: 0034040269     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200006000-00010     Document Type: Review

References (19)

1. 1 Cianflone K, Maslowska M, Sniderman AD. Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. Semin Cell Devel Biol 1999; 10:31-41. This review focuses also on the in vitro evidence that led to the description of the ASP pathway.
2. 2 Van Harmelen V, Reynisdottir S, Cianflone K, Degerman E, Hoffstedt J, Nilsell K, et al. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation stimulating protein and insulin. J Biol Chem 1999; 274:18243-18251. An important extension of the potential physiologic significance of the ASP pathway is provided. This article establishes that ASP is an important determinant of fatty acid release from adipocytes, as well as a critical determinant of their deposition. Furthermore, the actions of ASP are complementary to those of insulin in regulating fatty acid release. New insights are provided into the signal transduction mechanisms that are responsible for these effects of ASP.
3. 3 Olivecrona G, Olivecrona T. Triglyceride lipases and atherosclerosis. Curr Opin Lipidol 1995; 6:291-305.
4. 4 Sniderman AD, Cianflone K, Amer P, Summers L, Frayn K. The adipocyte, fatty acid trapping, and atherogenesis. Arterio Thromb Vasc Biol 1998; 18:147-151.
5. 5 Fielding BA, Frayn KN. Lipoprotein lipase and the disposition of dietary fatty acids. Br J Nutr 1998; 80:495-502.
6. 6 Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106:241-253.
7. 7 Lamarche B, Despres JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol 1995; 75:1189-1195.
8. 8 Murthy V, Julien P, Gagne C. Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol Ther 1996; 70:101-135.
9. 9 Cianflone K, Maslowska M, Sniderman AD. Impaired response to fibroblasts in patients with hyperapobetalipoproteinemia to acylation stimulating protein. J Clin Invest 1990; 85:722-730.
10. 10 Zhang XJ, Cianflone K, Genest J, Sniderman AD. Plasma acylation stimulating protein (ASP) as a predictor of impaired cellular biological response to ASP in patients with hyperapoB. Eur J Clin Invest 1998; 28:730-739.
11. 11 Frayn KN, Coppack SW, Humphreys SM. Subcutaneous adipose tissue metabolism studied by local catheterization. Int J Obes Relat Metab Disord 1993; 17 (Suppl 3):S18-S21.
12. 12 Saleh J, Summers LKM, Cianflone K, Fielding BA, Sniderman AD, Frayn KN. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J Lipid Res 1998; 39:884-891.
13. 13 Scantlebury T, Maslowska M, Cianflone K. Chylomicron specific enhancement of acylation stimulating protein (ASP) and precursor protein C3 production in differentiated human adipocytes. J Biol Chem 1998; 273:20903-20909.
14. 14 Charlesworth JA, Peake PW, Campbell LV, Pussell BA, O'Grady S, Tzilopoulos T. The influence of oral lipid loads on acylation stimulating protein (ASP) in healthy volunteers. Int J Obes Related Metab Dis 1998; 22:1096-1102.
15. 15 Wetsel RA, Kildsgaard J, Zsigmond E, Liao W, Chan L. Genetic deficiency of acylation stimulating protein (ASP/C3adesArg) does not cause hyperapobetalipoproteinemia in mice. J Biol Chem 1999; 274:19429-19433. In this study, triglyceride clearance was not delayed in ASP knockout mice, or was plasma apoB elevated. Accordingly, the authors concluded that the ASP pathway is not physiologically relevant.
16. 16 Murray I, Sniderman AD, Cianflone K. Mice lacking acylation stimulating protein (ASP) have delayed postprandial triglyceride clearance. J Lipid Res 1999; 40:1671-1676. In our study, plasma triglyceride clearance was delayed in the ASP knockout mice, an effect that was particularly evident in the males. Intraperitoneal injection of human ASP significantly accelerated triglyceride clearance in the knockout male animals.
17. 17 Murray I, Sniderman AD, Havel PJ, Cianflone K. Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice. J Biol Chem 1999; 274:36219-36225. This is a considerably more detailed study in male knockout and wild-type mice, which includes study of the effects of low-fat and high-fat diets, estimates of adipose tissue mass, glucose tolerance and leptin levels.
18. 18 Murray I, Havel PJ, Sniderman AD, Cianflone K. Reduced body weight, adipose tissue and leptin levels despite increased energy intake in female mice lacking acylation stimulating protein. Endocrinology 1999; 141:1041-1049. Studies similar to those above were carried out in female wild-type and knockout mice. The present review attempts to integrate the data from these two studies.
19. 19 Murray I, Sniderman AD, Cianflone K. Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein (ASP) in C571BI/6 mice. Am J Physiol Endocrinol Metab 1999; 277:E474-E480. The data from this study demonstrate that intraperitoneal injection of human ASP significantly accelerated triglyceride clearance, particularly in those animals in which it was not already accelerated at baseline. It represents clear evidence that the effect of ASP on triglyceride clearance, as distinguished from that on fatty acid trapping, is evident only when the clearance is already limited.